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ABSTRACTS
Gregory L. Moneta, MD, Abstracts Section EditorInhibition of annexin V binding to cardiolipin and thrombin genera-
tion in an unselected population with venous thrombosis
Hanly JG, Smith SA, Anderson D. J Rheumatol 2003;30:190-3.
Conclusion: Abnormalities in annexin V may contribute to the pro-
coagulant state in patients with idiopathic venous thrombosis.
Summary: The authors evaluated 111 patients who came to an
emergency room with symptoms suggestive of venous thromboembolism
(VTE). In 34 patients the diagnosis of lower extremity deep venous
thrombosis or pulmonary embolism was confirmed (VTE-positive
group). Seventy-seven patients with normal findings at diagnostic
workup for VTE composed the control group (VTE-negative group).
Plasma samples were collected before beginning anticoagulation, and
were examined for immunoglobulin G (IgG) anti-cardiolipin, IgG anti-
2-glycoprotein1, and IgG anti-prothrombin antibodies with an enzyme-
linked immunosorbent assay. They also examined the effect of individual
patient variables on control plasma samples of annexin V binding to
anti-cardiolipin and on in vitro thrombin generation determined with a
competitive enzyme-linked immunosorbent assay and a chromogenic
assay.
Prevalence and levels of IgG anti-cardiolipin, anti-2-glycoprotein 1,
and anti-prothrombin antibodies were similar in the groups with and with-
out VTE. Plasma samples from the VTE-positive group, however, caused a
significant inhibition of in vitro thrombin generation, and concurrent, less
impressive inhibition of annexin V binding to aCL. Only age and inhibition
of thrombin generation were significantly associated with VTE.
Comment: Despite improvement in detection of hypercoagulable
states, many patients with unprovoked VTE have, as yet, no identifiable
hypercoagulable abnormality. The study suggests that annexin V abnormal-
ities may result in a minor hypercoagulable state. It is still unclear whether
annexin V abnormalities can act in isolation to produce VTE.
A prospective registry of carotid angioplastine and stenting
Theiss W, Hermanek P, Mathias K, et al. Radiology 2004;35:2134-9.
Conclusion: Carotid angioplasty and stenting (CAS) may be per-
formedwith similar results in the community setting, as has been reported by
highly specialized centers and in clinical studies.
Summary: The German Societies of Angiology and Radiology insti-
tuted a prospective registry of CAS to limit its uncontrolled use and collect
data about technique and results of CAS outside of clinical trials. The
registry is open to investigators in Germany, Austria, and Switzerland who
are active in CAS. Thirty-eight centers participate. Patients are prospectively
interviewed before CAS is performed. At discharge from the hospital,
technical details, periprocedural medications, and clinical course are re-
ported on a standardized form.
After 4 years, 3853 planned interventions were recorded in the registry.
CASwas attempted in 3267 patients. Of these, 56% had symptomatic disease
and 44% had asymptomatic disease. In 98% of patients stents were used, 89%
of which were self-expanding. Other technical aspects of CAS, including
cerebral protection devices and methods of periprocedural monitoring,
varied widely among centers. Periprocedural medications generally included
aspirin and clopidogrel before and after CAS, and high-dose heparin and
atropine during CAS. CAS was technically successful in 3207 patients (98%).
In-hospital mortality was 0.6% (n  18). In-hospital major stroke rate was
1.2% (n  38), and in-hospital minor stroke rate was 1.3% (n  41).
Combined stroke and death rate was 2.8% (n  90).
Comment: There are ongoing trials to evaluate the efficacy of CAS
versus carotid endarterectomy. These trials will determine the relative utility
of the 2 procedures. In the meantime, studies such as this one can be used to
justify randomized trials of carotid endarterectomy versus CAS. Because of
the limitations of a registry format, and the very short-term follow up
(in-hospital only) of registry patients, this trial should not, and cannot, be
used to justify performance of CAS in the community setting.
Elevated plasma factor VIII and D-dimer levels as predictors of poor
outcome of thrombosis in children
Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ, and Mountain
States Regional Thrombophilia Group. N Engl J Med 2004;351:1081-8.
Conclusion: Elevated levels of plasma factor VIII, D-dimer, or both at
diagnosis and during follow-up after the standard duration of anticoagula-
tion therapy predict poor outcomes in children with thrombosis.
176Summary: Elevated levels of plasma factor VIII and D-dimer predict
recurrent venous thromboembolism in adults (N Engl J Med 2000;343:
457-62; Thromb Haemost 2002;87:7-12). The authors investigated
whether elevated levels of factor VIII, D-dimer, or both at diagnosis, and
persistence of these laboratory abnormalities after anticoagulation therapy
correlated with poor outcome of thrombosis in children, defined as those
from birth to age 21 years. Data analyzed were from Children’s Hospital in
Denver and hospitals participating in the Mountain States Regional Hemo-
philia and Thrombosis Center. The study included 144 children with
radiologically confirmed acute thrombotic events. All initially received hep-
arin therapy, followed by warfarin sodium for 3 to 6 months. Follow-up was
at 3, 6, and 12months, and then annually. Repeat thrombophilia testing was
performed in children with previously abnormal factor VIII and D-dimer
levels.
Complete data were available for analysis in 82 children. Of these 82
children, 67% had factor VIII levels greater than 150 IU/dL, D-dimer
levels greater than 5 ng/mL, or both, at diagnosis. In the 75 patients in
whom thrombophilia testing was performed after 3 to 6 months of
anticoagulation therapy, 43% had persistent elevation of at least 1 of these
2 laboratory values at a median follow-up of 12 months (range, 3
months–5 years), and 51% of the 82 patients had a poor outcome, such as
lack of thrombus resolution, recurrent thrombosis, or postthrombotic
syndrome. Elevated levels of factor VIII, D-dimer, or both at diagnosis
predicted a poor outcome, with an odds ratio of 6.1 (P  .008).
Persistence of at least 1 laboratory abnormality at 3 to 6 months also
predicted poor outcome, with an odds ratio of 4.7 (P  .002). A
combination of factor VIII level greater than 150 IU/dL and D-dimer
level greater than 5 ng/mL at diagnosis was predictive of poor outcome,
with 91% specificity. After 3 to 6 months of standard anticoagulation this
combination predicted poor outcome with 88% specificity.
Comment: Children with thrombosis should not be considered just
small adults. Children have lower concentrations of physiologic inhibitors of
the coagulation system and a more limited fibrolytic capacity than adults do.
These differences in the coagulation systems between adults and children are
particularly prominent in the first year of life and at puberty and adolescence
(Thromb Haemost 1995;74:415-25). This study’s identification of specific
levels of factor VIII and D-dimer in children with thrombosis should help
guide anticoagulation therapy in children and, it is hoped, reduce the burden
of late thrombosis-related complications in pediatric patients.
N-acetylcysteine vs fenoldopan mesylate to prevent contrast agent–
associated nephrotoxicity
Birguori C, Colombo A, Airoldi F, et al. Am J Cardiol 2004;44:762-5.
Conclusion: N-acetylcysteine (NAC) is more effective then fenoldo-
pan in preventing contrast agent–induced nephrotoxicity.
Summary: Both fenoldopan mesylate, a specific antagonist of the
dopamine-1 receptor, and NAC are thought to prevent contrast agent–
associated nephrotoxicity. The authors randomly assigned 192 consecutive
patients with chronic renal insufficiency who were referred for coronary or
peripheral procedures involving administration of contrast agents to receive
intravenous hydration with 0.45% saline solution and NAC (1200 mg orally
twice daily) or fenoldopan (0.10 g/kg/min) before and after nonionic
iso-osmolar contrast dye administration. There were 97 patients in the NAC
group, and 95 patients in the fenoldopan group.
Creatinine concentration was similar in the 2 groups of patients. The
amount of contrast medium administered was similar in the 2 groups (P 
.54). An increase in creatinine concentration of at least 0.5 mg/dL 48 hours
after the procedure occurred in 4 of 97 patients (4.1%) in the NAC group
and in 13 of 95 patients (13.7%) in the fenoldopan group (P  .019; odds
ratio, 0.27; 95% confidence interval, 0.08-0.85).
Comment: Fenoldopan is thought to potentially selectively increase
blood flow to the renal medulla. The findings of this study, however,
indicate that fenoldopan is ineffective in preventing further deterioration in
renal function in patients with chronic renal insufficiency receiving an
iodinated contrast agent. On the basis of these data, and considering the
high cost of fenoldopan, hydration plus fenoldopan should not be used as
prophylaxis to prevent contrast agent–associated neuropathy.
Endoluminal stent-graft placement for acute rupture of the descending
thoracic aorta
Scheinert D, Krankenberg H, Schmidt A, et al. Eur Heart J 2004;25:694-
700.
